Old Web
English
Sign In
Acemap
>
authorDetail
>
Larisa Reyderman
Larisa Reyderman
Merck & Co.
Medicine
Pharmacokinetics
Anesthesia
Pharmacodynamics
Vorapaxar
4
Papers
131
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers
2013
Clinical pharmacology in drug development
Teddy Kosoglou
Larisa Reyderman
Jack Tseng
Bharath Kumar
Fengjuan Xuan
James E. Schiller
Alan G. Meehan
Kenneth Kim
David L. Cutler
Show All
Source
Cite
Save
Citations (8)
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
2012
European Journal of Clinical Pharmacology
Teddy Kosoglou
Larisa Reyderman
Claudia Kasserra
Lisa K. Jennings
Sophia Young
Fengjuan Xuan
Jinglan Pei
Stephen E. Maxwell
James E. Schiller
Alan G. Meehan
David L. Cutler
Show All
Source
Cite
Save
Citations (21)
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
2012
European Journal of Clinical Pharmacology
Teddy Kosoglou
Larisa Reyderman
Renger G. Tiessen
Andre van Vliet
Robert R. Fales
Robert Keller
Bo Yang
David L. Cutler
Show All
Source
Cite
Save
Citations (82)
Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects
2008
Teddy Kosoglou
Larisa Reyderman
Claudia Kasserra
Sophia Young
Jinglan Pei
Stephen E. Maxwell
James E. Schiller
David L. Cutler
Show All
Source
Cite
Save
Citations (20)
1